Sanofi-Aventis (SNY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Sanofi-Aventis (SNY)

43.88

-1.14 (2.53%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

91 watching

Investor Insights

Jun 7, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Sanofi-Aventis, under the symbol SNY-N, has faced some challenges recently, with its performance triggering a stop at $47 according to Stockchase Research Editor Michael O'Reilly. The stock was previously highlighted as a top pick on June 5, 2025, but has since seen a decline of 6.5%. This indicates that while it had potential, the current market conditions have not favored the stock as hoped. Investors are advised to cover their positions to maintain discipline, suggesting a cautious approach moving forward. Overall, the sentiment around Sanofi-Aventis currently leans toward a reassessment of its value in the market, and investors may need to consider alternative strategies.

Consensus

Negative

Valuation

Overvalued

Similar

Pfizer,PFE

BUY

Many of the health care stocks have started to recover or they are not down as much as the market this year. 4% yield and decent growth over time.

BUY

Had as a toe-hold in the pharmaceutical group that has been out of favour for 3 years, but with only medium success. Facing competition from the generics. Has a great portfolio of drugs and has pretty steady growth.

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

Showing 46 to 48 of 48 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Sanofi-Aventis (SNY)